Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

← catalyst calendar

NCT06975878 · readout in 371 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Prevention

Enrollment

1,092actual

Sites

Countries

Belgium, Czechia, Estonia +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-05-22

actual

When the study began enrolling

Primary completion

2027-08-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-08-25

estimated

The whole study's end, after follow-up

First posted

2025-05-16

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Pneumococcal Immunization
Healthy Volunteers

Interventions

Biological: PCV21 vaccine — also filed as 515
Biological: Vaxneuvance vaccine — also filed as Vaxneuvance ™
Biological: Hexyon vaccine — also filed as Hexyon®
Biological: M-M-RvaxPro vaccine — also filed as M-M-RVAX-PRO®
Biological: Varivax vaccine — also filed as Varivax®

Primary outcomes

what the primary-completion date above is the date OF

Seroresponse rate for PCV21 and 15vPCV serotypes

measured 30 days post-toddler dose

IgG concentration for PCV21 and 15vPCV serotypes

measured 30 days post-toddler dose

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed